Fig E4.

Dual engagement of EP2 and EP4 receptors is essential for the PGE₂-induced reduction of ILC2 cytokine production. Sorted and expanded tonsillar ILC2s were stimulated as indicated for 24 hours. Additionally, the EP2 receptor antagonist PF-04418948 (PF) and the EP4 receptor antagonist ONO AE3-208 (ONO) were added separately or together in different concentrations (100 nmol/L, 300 nmol/L, 1 μmol/L, and 3 μmol/L) 20 minutes before PGE₂. A and B, Concentrations of released IL-5 (Fig E4, A) and IL-13 (Fig E4, B) in ILC2 supernatants were determined by using ELISA and shown as means ± SEM (n = 4). C and D, Sorted and expanded tonsillar ILC2s were treated with the EP2 receptor agonist butaprost (But) and the EP4 receptor agonist L-902,688 (L9) separately or together in different concentrations (10 nmol/L, 30 nmol/L, 100 nmol/L, 300 nmol/L, and 1 μmol/L) 10 minutes before the stimulatory cytokines. Concentrations of released IL-5 (Fig E4, C) and IL-13 (Fig E4, D) in ILC2 supernatants were determined by using ELISA and are shown as means ± SEMs (n = 4; compared with IL treatment). *P < .05 and **P < .01. ns, Nonstimulated.